|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical Observation of Transepithelial Corneal Collagen Cross-linking by Iontophoresis of Riboflavin in Treatment of Keratoconus显示文摘Purpose: To evaluate the efficacy and safety of transepithelial collagen cross-linking by iontophoretic delivery of riboflavin in treatment of progressive keratoconus.Methods:.Eleven patients(15 eyes) with progressive keratoconus were enrolled. After 0.1% riboflavin-distilled water solution was deliveried via transepithelial iontophpresis for 5 min with 1 m A current, and ultraviolet radiation(370 nm,.3 m W /cm2) was performed at a 1.5 cm distance for 30 min. The follow up were 6 months in all eyes. The uncorrected visual acuity, corrected visual acuity,endothelial cell counting, corneal thickness,.intraocular pressure, corneal curvature, corneal topography,.OCT and corneal opacity before and 6-month after surgery were analyzed.Results: At 6 month postoperatively, mean uncorrected visual acuity and corrected visual acuity changed from 0.36 to 0.30 and from 0.42 to 0.57 without statistical significance..The mean value of each index of corneal curvature declined without statistical significance.Kmax value dereased from 60.91 to59.91, and the astigmatism declined from 3.86 to 3.19. Central corneal thickness decreased from 460.93 μm to 455.40μm,.and thinnest corneal thickness declined from 450.87 μm to 440.60 μm with no statistical significance..Intraocular pressure was significantly elevated from 10.85 mm Hg to 12.62 mm Hg. Endothelial cell count did not change significantly. No corneal haze occurred. Mean depth of corneal demarcation line was 288.46 μm at 1 month postoperatively..Conclusion:.Transepithelial corneal collagen cross-linking by iontophoresis is effective and safe in the treatment of progressive keratoconus, and yields stable clinical outcomes during 6-month follow up..However,.long-term follow up is urgently required. | Na Li Zhengjun Fan Xiujun Peng Xu Pang Chunyu Tian | 2014 | Eye Science2014，29，3： | 15 |
| 2 | 离子导入辅助跨上皮角膜胶原交联治疗进展期圆锥角膜2a随访分析显示文摘目的:报道离子导入辅助跨上皮角膜胶原交联(iontophoresis-assited transepithelial corneal collagen crosslinking,I-CXL)治疗进展期圆锥角膜的2a观察结果。方法:选取进展期圆锥角膜患者24例34眼,应用1g/L核黄素蒸馏水溶液,离子导入(1m A电流)辅助跨上皮给药5min后,紫外线A(370nm,3m W/cm^2)照射30min。观察术前和术后2a最佳矫正视力(best corrected distance visual acuity,BCVA)、角膜散光度数、K1、K2、Kmean、Kmax、眼压、角膜内皮细胞密度、角膜顶点厚度、角膜最薄厚度变化。结果:术后2a,BCVA(Log MAR)从0.32±0.25提高到0.25±0.19,差异具有统计学意义(t=2.849,P=0.015),K1从47.12±4.33下降到46.06±4.77,差异具有统计学意义(t=2.652,P=0.015),K2从51.36±5.59下降到50.40±6.16,差异具有统计学意义(t=2.121,P=0.047),Kmean从49.12±4.76下降到48.10±5.25,差异具有统计学意义(t=2.663,P=0.015),Kmax从57.57±8.30下降到55.91±8.14,差异具有统计学意义(t=2.398,P=0.026),角膜顶点厚度从476.90±38.71下降到454.43±40.86μm(t=2.853,P=0.010),角膜最薄厚度从464.38±39.92下降到433.86±50.78μm,差异具有统计学意义(t=3.485,P=0.002)。角膜散光度数、眼压和角膜内皮细胞密度无明显变化。结论:I-CXL治疗进展期圆锥角膜安全、有效,2a内能够阻止进展期圆锥角膜病情恶化,但长期效果仍需进一步观察。 | 贾洪真 庞旭 樊郑军 彭秀军 | 2016 | 国际眼科杂志2016，16，7： | 6 |
| 3 | Efficacy of iontophoresis-assisted epithelium-on corneal cross-linking for keratoconus显示文摘Corneal cross-linking(CXL) is a noninvasive therapeutic procedure for keratoconus that is aimed at improving corneal biomechanical properties by induction of covalent cross-links between stromal proteins. It is accomplished by ultraviolet A(UVA) radiation of the cornea, which is first saturated with photosensitizing riboflavin. It has been shown that standard epithelium-off CXL(S-CXL) is efficacious, and it has been recommended as the standard of care procedure for keratoconus. However, epithelial removal leads to pain, transient vision loss, and a higher risk of corneal infection. To avoid these disadvantages, transepithelial CXL was developed. Recently, iontophoresis has been adopted to increase riboflavin penetration through the epithelium. Several clinical observations have demonstrated the safety and efficacy of iontophoresisassisted epithelium-on CXL(I-CXL) for keratoconus. This review aimed to provide a comprehensive summary of the published studies regarding I-CXL and a comparison between I-CXL and S-CXL. All articles used in this review were mainly retrieved from the Pub Med database. Original articles and reviews were selected if they were related to the I-CXL technique or related to the comparison between I-CXL and S-CXL. | Hong-Zhen Jia Xiu-Jun Peng | 2018 | International Journal of Ophthalmology(English edition)2018，11，4： | 2 |
| 4 | 应用两种不同核黄素溶液的离子导入交联治疗进展期圆锥角膜后基质分界线深度比较显示文摘目的比较应用0.1%核黄素蒸馏水溶液的离子导入交联与应用0.1%核黄素乳酸钠林格液的离子导入交联治疗进展期圆锥角膜后基质分界线的深度。方法选取2013年1月-2013年7月行0.1%核黄素乳酸钠林格液离子导入交联治疗进展期圆锥角膜11例患者16眼和2013年8月-2015年11月行0.1%核黄素蒸馏水溶液离子导入交联治疗进展期圆锥角膜62例患者78眼的眼科资料。比较治疗1个月后两组前节OCT检查的基质分界线深度。结果 0.1%核黄素乳酸钠林格液离子导入角膜交联组分界线深度为(268.25±18.06)μm,0.1%核黄素蒸馏水溶液离子导入角膜交联组分界线深度为(298.95±51.97)μm,差异有统计学意义(t=3.594,P=0.001)。两组分界线发生数量分别为9眼(9/16)和65眼(65/78),差异有统计学意义(χ~2=5.514,P=0.019)。结论 0.1%核黄素蒸馏水溶液离子导入角膜交联治疗进展期圆锥角膜效果可能优于0.1%核黄素乳酸钠林格液离子导入角膜交联。 | 贾洪真 庞旭 李刚 李娜 隋艳来 樊郑军 彭秀军 | 2017 | 解放军医学院学报2017，38，9： | 2 |
| 5 | Iontophoresis-assisted corneal crosslinking using 0.1% riboflavin for progressive keratoconus显示文摘AIM:To report the clinical results of iontophoresis-assisted epithelium-on corneal crosslinking(I-CXL) using 0.1% riboflavin in distilled water for progressive keratoconus. METHODS:In this prospective clinical study, we examined 94 eyes of 75 patients with progressive keratoconus who were treated with I-CXL using 0.1% riboflavin in distilled water. Best correct visual acuity(BCVA), Scheimpflug tomography, corneal topography, anterior segment optical coherence tomography, intraocular pressure, and endothelial cell density were evaluated at baseline and 1, 3, 6, 12, and 24 mo after I-CXL.RESULTS:After 24 mo I-CXL, compared to the level at baseline, BCVA significantly improved 0.14±0.07(P=0.010); mean keratometry signifi cantly decreased 0.72±1.97(P=0.021); maximum keratometry significantly reduced 2.30±5.01(P=0.014); central keratoconus index significantly reduced 0.04±0.08(P=0.007). The demarcation line was visible in 83.1% of eyes at 1mo after treatment, with a depth of 298.95±51.97 μm, and gradually indistinguishable. One eye had repeat treatment. Intraocular pressure and endothelial cell density did not change significantly.CONCLUSION:I-CXL using 0.1% riboflavin halts keratoconus progression within 24 mo, resulting in a significant improvement in visual and topographic parameters. Moreover, the depth of the demarcation line is similar to that previously reported in standard epithelium-off CXL procedures. | Hong-Zhen Jia Xu Pang Zheng-Jun Fan Na Li Gang Li Xiu-Jun Peng | 2017 | International Journal of Ophthalmology(English edition)2017，10，5： | 1 |
| 6 | 角膜胶原交联术应用与进展显示文摘角膜胶原交联术是一种用于增加角膜硬度和生物力学稳定性的手术。该手术的原理是紫外光照射滴加了核黄素的角膜,角膜组织发生光化学反应,并诱导角膜的胶原纤维间产生共价键连接,从而增强角膜生物化学和生物力学的稳定性。临床上多用于圆锥角膜的治疗,然而随着技术的改进,目前角膜胶原交联术还可用于治疗感染性角膜炎和低度近视。本文就角膜胶原交联术的原理、安全性与有效性、临床应用局限性与副作用、新型治疗技术以及未来发展方向等方面进行综述讨论。 | 陈水莲 张晶 吴奕辉 邱瑾 庄菁 余克明 | 2018 | 广东医学2018，39，3： | 1 |
| 7 | Iontophoresis-assisted versus standard corneal crosslinking for progressive keratoconus显示文摘Background:To compare the safety and efficacy of iontophoresis-assisted epithelial-on corneal crosslinking(I-CXL)using 0.1%riboflavin-distilled water solution with standard epithelium-off corneal crosslinking(S-CXL)for progressive keratoconus.Methods:In a retrospective analysis,progressive keratoconus patients treated with I-CXL(17 eyes of 17 patients)or S-CXL(13 eyes of 13 patients)were included.All patients were followed up at least 12 months.All patients underwent detailed ophthalmologic examinations involving pre-and postoperative visual acuity,topographic parameters and pachymetry.Intra-and postoperative complications were recorded.Results:No statistically significant differences were observed between the two groups at baseline with respect to visual acuity,age and thinnest corneal thickness(TCT).The postoperative decreases of K1 and Kmean in the S-CXL group represented statistically significantly better results than in the I-CXL group(t=2.093 and 2.123,P=0.046 and 0.043,respectively).Alterations of other parameters showed no significant differences between the two groups.There were no failure cases in the two groups.Conclusions:I-CXL using 0.1%riboflavin-distilled water solution provided effective treatment for progressive keratoconus at 12-month follow-up.However,the decreases of K1 and Kmean caused by I-CXL were less than those by S-CXL.Although treatment time,postoperative patient pain and risk of infection in I-CXL are all less than those in S-CXL,I-CXL is unable to completely replace S-CXL for progressive keratoconus temporarily. | Hong-Zhen Jia Xu Pang Zheng-Jun Fan Xiu-Jun Peng | 2017 | Annals of Eye Science2017，，1： | 0 |
| 8 | 离子导入辅助角膜交联治疗青少年圆锥角膜(英文)显示文摘目的:评估离子导入辅助的跨上皮角膜交联治疗青少年圆锥角膜的安全性和有效性。方法:搜集12例(年龄12!18岁,平均15.8±2.08岁)进展期圆锥角膜患者,共15眼,采用0.1%核黄素蒸馏水溶液,离子导入(1 m A电流)辅助跨上皮给药5min,紫外线A(370 nm,3 m W/cm^2)照射30min。记录术前、术后3mo和1a的裸眼视力、最佳矫正视力、K_1、K_2、最大K值、平均K值、角膜散光度数、角膜内皮细胞密度、眼内压、最薄角膜厚度、角膜顶点厚度。角膜参数应用角膜地形图评估,角膜内皮细胞密度应用非接触角膜内皮镜检查。结果:角膜交联1a后,裸眼视力、最佳矫正视力、K_1、K_2、最大K值、平均K值、角膜散光度数、角膜内皮细胞密度和眼内压均无显著变化。最薄角膜厚度从468.08±33.40μm下降到447.46±40.20μm(t=4.379,P=0.001),差异有统计学意义。角膜顶点厚度从476.07±35.96μm下降到454.60±49.32μm(t=4.270,P=0.001),差异有统计学意义。结论:采用0.1%核黄素蒸馏水溶液的离子导入辅助的角膜交联治疗青少年圆锥角膜是安全、有效的,1a内能够阻止病情恶化,但是长期效果有待于进一步观察。 | 贾洪真 庞旭 李娜 李刚 樊郑军 彭秀军 | 2016 | 国际眼科杂志2016，16，12： | 0 |
| 9 | 三种不同方案角膜交联后角膜厚度减小量的比较显示文摘目的评估三种不同方案角膜交联(corneal crosslinking,CXL)治疗进展期圆锥角膜后最薄角膜厚度(thinnest-point corneal thickness,TCT)减小量的差异。方法回顾性临床病例研究。选取2010年8月至2015年11月在海军总医院眼科确诊并行CXL治疗的进展期圆锥角膜连续性病例85例(110眼)。21例(25眼)行标准的去上皮CXL(standard epithelium-off corneal crosslinking,S-CXL)治疗;14例(22眼)行1 g·L^(-1)核黄素乳酸钠林格液离子导入CXL(iontophoresis-assisted CXL,I-CXLa)治疗;50例(63眼)行1 g·L^(-1)核黄素蒸馏水溶液离子导入CXL(iontophoresis-assisted CXL,I-CXLb)治疗。应用ALLEGRO眼前节分析仪测量术前、术后TCT,比较三种CXL方案术后TCT减小量的差异。结果 S-CXL术后3个月、6个月、12个月TCT与术前差值分别为(-14.93±27.16)μm、(-31.94±22.89)μm、(-27.71±26.01)μm;I-CXLa术后3个月、6个月、12个月TCT与术前差值分别为(-20.14±19.09)μm、(-10.10±24.28)μm、(-7.11±22.26)μm;I-CXLb术后3个月、6个月、12个月TCT与术前差值分别为(-28.08±26.14)μm、(-21.08±25.62)μm、(-15.91±19.19)μm。术后3个月时,三组TCT减小量差异没有统计学意义(P=0.188);术后6个月、12个月时,S-CXL组和I-CXLa组比较差异均有统计学意义(均为P<0.05),I-CXLb组和S-CXL组、I-CXLb组和I-CXLa组比较差异均无统计学意义(均为P>0.05)。结论三种CXL方案治疗术后6个月和12个月,TCT减小量与交联方案相关,反映了交联强度的大小。I-CXLb术后TCT减小量小于S-CXL,但差异不显著,两者交联强度差异亦不显著。 | 贾洪真 庞旭 樊郑军 隋艳来 彭秀军 | 2017 | 眼科新进展2017，37，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员